


Ask a doctor about a prescription for LORAZEPAM CINFA 1 mg TABLETS
Package Leaflet: Information for the User
lorazepam cinfa 1 mg tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Contents of the pack and additional information
Lorazepam cinfa is a tranquilizer-anxiolytic (prevents nervousness and anxiety) that acts without influencing the normal activities of the individual. It complements antidepressant therapy and can be combined with antidepressant medications and other psychotropic drugs.
Lorazepam is used in the following cases:
Sleep disorders.
Do not take lorazepam cinfa
Warnings and precautions
Consult your doctor or pharmacist before starting to take lorazepam cinfa:
Dependence
Continuous use of benzodiazepines for several weeks can lead to some loss of efficacy with respect to hypnotic effects. It can also lead to dependence. This usually occurs mainly after uninterrupted use of the medication for a long time.
To minimize this risk, the following instructions should be taken into account:
Tolerance
After continuous use for several weeks, some degree of loss of efficacy with respect to hypnotic effects may be detected.
Amnesia
Benzodiazepines can induce amnesia. This fact occurs more frequently several hours after administration of the medication, so to minimize the associated risk, patients should ensure they sleep uninterruptedly for 7-8 hours after taking the tablet.
Psychiatric and paradoxical reactions
In treatment with benzodiazepines, pre-existing depressions or worsening of the depressive state may reappear. Additionally, suicidal tendencies in depressive patients may be masked, which should be monitored in these patients.
Other medications and lorazepam cinfa
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
It should be taken into account that all benzodiazepines produce depressant effects on the central nervous system (CNS), if administered together with barbiturates or alcohol.
When lorazepam is taken with other medications that act on the CNS, the combination can make you feel more drowsy than necessary. These medications include:
Similarly, the concomitant administration of lorazepam with other medications can alter the effect of lorazepam, prolonging or decreasing its activity. These medications include:
Taking lorazepam cinfa with food, drinks, and alcohol
Lorazepam can be taken with or without food.
Alcohol increases the sedative effect of this medication, so it is recommended to avoid consuming alcoholic beverages.
Pregnancy and breastfeeding
Consult your doctor or pharmacist before using any medication.
Pregnancy:
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
The use of benzodiazepines appears to be related to a possible increased risk of congenital malformations in the first trimester of pregnancy. The passage of benzodiazepines and their derivatives through the placenta has been detected.
If, on medical recommendation, the product is administered during a late stage of pregnancy or at high doses during childbirth, it is foreseeable that effects on the newborn such as hypoactivity, hypothermia (drop in body temperature), hypotonia (decrease in muscle tone), apnea (period of lack of breathing), moderate respiratory depression, feeding problems, and metabolic response imbalance to stress due to cold may appear.
Children born to mothers who take benzodiazepines chronically during several weeks of pregnancy or during the last period of pregnancy may develop physical dependence and trigger withdrawal syndrome in the postnatal period.
Breastfeeding:
This medication should not be used during breastfeeding, as benzodiazepines are excreted in breast milk. Cases of sedation and inability to breastfeed have been detected in newborns whose mothers were under treatment with benzodiazepines. These newborns should be monitored to detect any of the mentioned pharmacological effects (sedation and irritability).
Use in children, elderly patients, and debilitated patients
Benzodiazepines are not recommended in children under 6 years of age unless strictly necessary; the duration of treatment should be as short as possible. Elderly patients and debilitated patients should receive a lower dose, as they are more susceptible to the effects of the medication.
Use in patients with respiratory failure
Lower doses are recommended in patients with chronic respiratory failure due to the associated risk of respiratory depression, such as in patients with chronic obstructive pulmonary disease (COPD) or sleep apnea syndrome.
Driving and using machines
Lorazepam may alter your ability to drive or operate machinery, as it can cause drowsiness, decrease your attention, or decrease your reaction capacity. The appearance of these effects is more likely at the start of treatment or when the dose is increased. Do not drive or use machines if you experience any of these effects.
lorazepam cinfa contains lactose.
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
lorazepam cinfa contains sodium.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; that is, it is essentially "sodium-free".
Follow the administration instructions of this medication exactly as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The tablet can be divided into equal doses.
Your doctor will indicate the duration of your treatment. Do not stop treatment before it is finished, as it may not have the desired effect.
Anxiety:
The recommended initial dose in anxiety states is 0.5 to 3 mg per day, divided into several doses, administered orally, with or without food. This dose may be increased or decreased according to the needs or age of the patient and at the doctor's discretion.
The duration of treatment should be as short as possible. Your doctor should regularly reassess your situation. In general, the total duration of treatment should not exceed 8-12 weeks, including gradual withdrawal.
Insomnia:
Treatment should begin with the lowest recommended dose, 1 mg in a single dose at bedtime, gradually increasing until the effective dose is achieved. The maximum dose should not exceed 4 mg.
In general, the duration of treatment should be as short as possible, ranging from a few days to two weeks, with a maximum duration of four weeks, including gradual withdrawal of the medication. Your doctor will indicate the dose you should take at each time.
In certain cases, it may be necessary to prolong treatment beyond the recommended period; this decision can only be made by your doctor.
Use in children
There is no data available in children (under 6 years of age), and therefore, the prescription of lorazepam is not recommended for young children.
Use in elderly patients
In elderly patients, the recommended dose is half a tablet (0.5 mg) per day, which can be gradually adjusted if necessary.
Use in patients with kidney problems
In patients with kidney problems, the recommended dose is half a tablet (0.5 mg) per day, which can be gradually adjusted if necessary.
Use in patients with liver problems
In patients with liver problems, the recommended dose is half a tablet (0.5 mg) per day, which can be gradually adjusted if necessary.
If you take more lorazepam cinfa than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, or call the Toxicology Information Service (Telephone: 91 562 04 20), indicating the medication and the amount ingested.
The most frequent symptoms of poisoning are: excessive drowsiness, confusion, or coma.
Treatment of overdose includes induction of vomiting or gastric lavage, general maintenance measures, adequate respiration, monitoring of vital signs, and proper patient control. Flumazenil can be used as an antidote. In patients who take benzodiazepines chronically, special care should be taken when administering flumazenil, as this combination of medications can increase the risk of seizures.
If you forget to take lorazepam cinfa
Take your tablet as soon as you remember. Do not take a double dose to make up for forgotten doses.
If you stop taking lorazepam cinfa
When stopping the administration, the symptoms that led to the taking of the medication may reappear, as well as restlessness, muscle pain, anxiety, tension, unease, confusion, and irritability, insomnia, lack of concentration, headache, sweating, depression, rebound phenomena, depersonalization (disconnection from reality), dizziness, depersonalization (disconnection from reality), involuntary movements, nausea, vomiting, diarrhea, loss of appetite, tremors, abdominal cramps, palpitations, tachycardia, panic attacks, vertigo, hyperreflexia (excessive stimulation), short-term memory loss, and hyperthermia (increase in body temperature), so your doctor will indicate precisely how to gradually decrease the dose.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
The following adverse effects are described in relation to their frequency of occurrence:
Very common May affect more than 1 in 10 people.
Common May affect up to 1 in 10 people.
Uncommon May affect up to 1 in 100 people.
Rare May affect up to 1 in 1,000 people.
Very rare May affect up to 1 in 10,000 people.
Frequency not known | Cannot be estimated from the available data. |
Disorders of the Blood and Lymphatic System
Frequency not known: Thrombocytopenia (decrease in blood platelets), agranulocytosis (decrease in neutrophils, a type of white blood cell) and pancytopenia (significant decrease in all blood cells).
Disorders of the Immune System
Frequency not known: Hypersensitivity and anaphylactic/anaphylactoid reactions (allergic).
Endocrine Disorders
Frequency not known: Syndrome of inappropriate antidiuretic hormone secretion.
Metabolic and Nutritional Disorders
Frequency not known: Hyponatremia (lack of sodium).
Psychiatric Disorders
Common: Confusion, depression, unmasking of depression.
Uncommon: Change in libido (sexual desire), decrease in orgasms.
Frequency not known: Disinhibition, euphoria, suicidal thoughts and attempts, paradoxical reactions such as anxiety, agitation, excitement, hostility, aggression, fury, sleep disturbances/insomnia, sexual desire, and hallucinations.
Disorders of the Nervous System
Very common: Feeling of suffocation.
Common: Ataxia (motor coordination and speech problems), dizziness.
Frequency not known: Extrapyramidal symptoms: tremor, dysarthria (difficulty articulating words), headache, convulsions; amnesia, coma, attention/concentration disorders, balance disorders.
Ocular Disorders
Frequency not known: Visual problems (double vision and blurred vision).
Disorders of the Ear and Labyrinth
Frequency not known: Vertigo.
Vascular Disorders
Frequency not known: Hypotension (decrease in blood pressure).
Respiratory, Thoracic, and Mediastinal Disorders
Frequency not known: Respiratory failure, apnea, worsening of sleep apnea. Worsening of chronic obstructive pulmonary disease (COPD).
Gastrointestinal Disorders
Uncommon: Nausea
Frequency not known: Constipation.
Hepatobiliary Disorders
Frequency not known: Jaundice (yellowing of the whites of the eyes and skin).
Disorders of the Skin and Subcutaneous Tissue
Frequency not known: Angioedema (swelling under the skin of the tongue, glottis, or larynx that can cause respiratory obstruction that can be fatal), allergic skin reactions, alopecia (hair loss).
Musculoskeletal and Connective Tissue Disorders
Common: Muscle weakness.
Disorders of the Reproductive System and Breast
Uncommon: Impotence.
General Disorders and Administration Site Conditions
Very common: Feeling of suffocation.
Common: Asthenia (fatigue and tiredness).
Frequency not known: Hypothermia (decrease in body temperature).
Investigations
Frequency not known: Increased bilirubin, increased transaminases, and increased alkaline phosphatase (liver enzymes).
As previously indicated, withdrawal of the product may cause the reappearance of certain symptoms as a consequence of dependence.
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Do not store at a temperature above 25°C.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging after "CAD". The expiration date is the last day of the month indicated.
Medicines should not be thrown away through the drains or into the trash. Deposit the packaging and medicines that you no longer need in the SIGRE Point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This way, you will help protect the environment.
Composition of Lorazepam Cinfa
Appearance of the Product and Package Contents
Lorazepam Cinfa is presented in the form of white, cylindrical, biconvex tablets, scored on one side and marked with the code "L1" on the other.
It is presented in PVC-PVDC/Aluminum blisters.
Each package contains 25, 50, or 500 (clinical package) tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer:
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta.
31620 Huarte (Navarra) - Spain
Date of the Last Revision of this Prospectus:July 2021
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
You can access detailed and updated information about this medicine by scanning the QR code included in the prospectus and packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/68477/P_68477.html
QR code to: https://cima.aemps.es/cima/dochtml/p/68477/P_68477.html
The average price of LORAZEPAM CINFA 1 mg TABLETS in October, 2025 is around 1.37 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for LORAZEPAM CINFA 1 mg TABLETS – subject to medical assessment and local rules.